Casdin Leads a Biopharma Surge

Several funds that lost large amounts last year rebounded nicely in the first month of 2023.

Toru Hanai/Bloomberg

Toru Hanai/Bloomberg

Finally some good news for investors in Casdin Capital.

The firm’s biopharma hedge fund posted a 20 percent gain in January, an encouraging start to the year in what was a mixed month for the strategy in general.

Casdin, however, has a long way to go to return to its high-water mark.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.